Pasithea Therapeutics announces 1-for-20 reverse stock split effective January 2, 2024

Pasithea Therapeutics Corp.

Reverse split ratio of 1-for-20; authorized shares reduced from 495M to 100M.
Effective at market open on January 2, 2024; CUSIP changes to 70261F202.
No fractional shares issued; cash payment based on 5-day average closing price pre-split.
All outstanding options, warrants, and convertible debt adjusted proportionately.
Board approved the split on Dec 21; shareholders authorized at Dec 19 annual meeting.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Pasithea Therapeutics Corp.: Reverse stock split via Certificate of Amendment to Amended and Restated Certificate of Incorporation (effective 2024-01-02).

Change: charter amendment
Effective: 2024-01-02

Exact text from the filing

On December 28, 2023, Pasithea Therapeutics Corp. (the “Company”) filed a Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Company with the Secretary of State of the State of Delaware (the “Certificate of Amendment”), reflecting a one-for-twenty reverse stock split

View on SEC.gov

71 governance changes filed in the last 30 days. Browse all governance changes →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-23-099115

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.